期刊文献+

1型糖尿病大鼠肾脏Ⅳ型胶原的表达及坎地沙坦的干预作用 被引量:3

下载PDF
导出
摘要 目的探讨1型糖尿病大鼠造模后肾脏Ⅳ型胶原的表达及肾小球病理形态改变及坎地沙坦的保护作用和机制。方法雄性Wistar大鼠36只,随机分出正常对照组(NC组)12只,余24只腹腔注射链脲佐菌素诱导糖尿病大鼠模型,再随机分为糖尿病组(DM组)12只和坎地沙坦干预组(DMC组)12只;DM-C组给予坎地沙坦5mg·kg-1·d-1灌胃。干预12w后,检测各组大鼠的空腹血糖(FPG)、血压、24h尿白蛋白排泄量(24hUAE)、肌酐清除率(Ccr)、肾重指数(KI);光镜下观察肾小球病理形态改变,测定肾小球平均截面积(MGA)、肾小球平均体积(MGV)和肾小球系膜基质分数(MMF);免疫组化法检测肾小球Ⅳ型胶原的表达。结果与NC组相比,DM组大鼠的FPG、24hUAE、Ccr及KI均显著升高(P<0.01),MGA、MGV及MMF显著增大(P<0.01),肾小球Ⅳ型胶原的表达明显增加(P<0.01);DMC组较DM组肾小球Ⅳ型胶原的表达明显减少(P<0.01),FPG、24hUAE、Ccr及KI均显著降低(P<0.01),MGA、MGV及MMF显著减小(P<0.01);三组间大鼠血压差异无统计学意义(P>0.05)。结论糖尿病大鼠肾脏Ⅳ型胶原表达增加;坎地沙坦具有独立于降压以外的肾脏保护作用。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2011年第2期286-287,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献6

  • 1Ota T,Takamura T,Ando H,et al.Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model[J].Diabetologia,2003;46(6):843-51.
  • 2Soslow RA,Dannenberg AJ,Rush D,et al.Cox-2 is expressed in human pulmonary,colonic,and mammary tumors[J].Cancer,2000;89(12):2637-45.
  • 3Charonis AS,Tsilbary EC.Structural and functional changes of laminin and typeIV collagen after nonenzymatic glycation[J].Diabetes,1992;41(2):49-51.
  • 4Parving HH,Lehnert H,Brochner-Mortensen J,et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J].N Engl J Med,2001;345(12):870-8.
  • 5Brenner BM,Cooper ME,de Zeeuw D,et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,2001;345(12):861-9.
  • 6Lewis EJ,Hunsicker LG,Clarke WR,et al.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[J].N Engl J Med,2001;345(12):851-60.

同被引文献32

  • 1李忠亮,常冰玲.血塞通治疗糖尿病肾病的疗效观察[J].中国误诊学杂志,2005,5(11):2031-2032. 被引量:13
  • 2徐静,李忠诚,易兰兰,王俊宏,张春虹,戴信刚,杨新利.蛋白激酶C和TGF-β1在糖尿病大鼠肾脏中的表达[J].中国老年学杂志,2006,26(3):343-345. 被引量:4
  • 3曹闻,张莹雯.黄芪多糖冲剂治疗糖尿病肾病的临床观察[J].湖北中医杂志,2007,29(4):12-13. 被引量:12
  • 4陈东晖,黄海云,丁一.层粘连蛋白-5结构及功能的研究进展[J].国际口腔医学杂志,2007,34(3):181-184. 被引量:3
  • 5Choi ME, Kim EG, Huang Q, et al. Rat mesangial cell hypertrophy in respones to transforming growth factor-betal [J]. Kidney Int,1993,44(5):948-58.
  • 6Shankland SJ, Scholey JW, Ly H, et al. Expression of trans- forming growth factor-beta 1 during diabetic renal hypertrophy [J]. Kidney Int,1994,46(2):430-442.
  • 7Young BA, Johnson R J, Alpers CE, et al. Cellular events in the evolution of experimental diabetic nephropathy Ill. Kidney lnt, 1995,47(3):935-44.
  • 8Kurogi Y. Mesangial cell proliferation inhibitors for the treat- ment of prollferative glomerular disease [I]. Med Res Re~', 2003,23(1):15-3l.
  • 9Wang SN, Hirschberg R. Growth factor ultrafihration in experi- mental diabetic nephropathy contributes to interstitial fibrosis [J].Am J Physiol Renal Physiol, 2000,278(4):554-60.
  • 10Sumida Y, Ura H, Yano Y, et al. Abnormal metabolism of type - 1V collagen in normotensive non insulin -depen- dent diabetes mellitus patients [J]. Horm Res,1997,48(1):23-28.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部